Observational studyBritish journal of clinical pharmacology2018
Patterns and profiles of methylphenidate use both in children and adults.
Observational study in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Psychoactive prescription drug use and misuse in patients on opioid agonist treatment.British journal of clinical pharmacology · 2026Article
- ADHD medication dispensing trends in Dutch youth before and after the implementation of the Youth Act (2010-2022).European child & adolescent psychiatry · 2025Article
- Mental Health Care Utilization and Prescription Rates Among Children, Adolescents, and Young Adults in France.JAMA network open · 2025Article
- Long-term methylphenidate use for children and adolescents with attention deficit hyperactivity disorder and risk for depression, conduct disorder, and psychotic disorder: a nationwide longitudinal cohort study in South Korea.Child and adolescent psychiatry and mental health · 2022Article
- ADHD diagnosis and methylphenidate consumption in children and adolescents: A systematic analysis of health databases in France over the period 2010-2019.Frontiers in psychiatry · 2022Article
- Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.Psychopharmacology · 2021Review
- Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment.Molecular psychiatry · 2021Article
- The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.European journal of clinical pharmacology · 2021Observational
- First-Time Users of ADHD Medication Among Children and Adolescents in Germany: An Evaluation of Adherence to Prescribing Guidelines Based on Claims Data.Frontiers in psychiatry · 2021Article
- Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty - United States, 2014-2019.Drug and alcohol dependence · 2020Article
- Short term methylphenidate treatment does not increase myocardial injury in the ischemic rat heart.Physiological research · 2020Article
- Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe.Journal of child and adolescent psychopharmacology · 2020Article
- Article
- Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.Pharmacology, biochemistry, and behavior · 2019Article
- Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018.British journal of clinical pharmacology · 2019Article
- Attention-Deficit/Hyperactivity Disorder and Transitional Aged Youth.Current psychiatry reports · 2018Review
- Patterns and profiles of methylphenidate use both in children and adults.British journal of clinical pharmacology · 2018Observational
- The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery.Frontiers in synaptic neuroscience · 2018Review
- Overuse of methylphenidate: an analysis of Swedish pharmacy dispensing data.Clinical epidemiology · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of the present study was to characterize patterns of use of methylphenidate (MPH), a prescription stimulant medication recommended in the treatment of attention deficit hyperactivity disorder (ADHD) and of narcolepsy, in France, both in children and adults, over a 3-year period.
methodsUsing the French General Health Insurance database, limited to two areas covering approximately 4 million individuals, we made up a cohort of incident MPH users between July 2010 and June 2013. Splitting them into distinct age groups (18-24, 25-49 and ≥50 years of age for adults and <6, 6-11 and 12-17 years of age for children), we established the characteristics of these populations at MPH initiation and during follow-up according to the duration of treatment, quantities dispensed and coprescription with central nervous system (CNS) drugs.
resultsWe included a cohort of 3534 incident users, involving 30 238 dispensings of MPH, leading to an annual rate of 29 incident users per 100 000 in 2013. Children (66% of new users) were characterized by long-term use of MPH with few comedications. The group of 25-49-year-old patients were dispensed MPH more frequently than other groups, had the highest mean dose and were more often coprescribed other CNS drugs. The ≥50 year-old group was more often coprescribed antidepressants and antiparkinsonian drugs.
conclusionsOur pharmacoepidemiological study involving incident MPH users with a large number of characteristics showed different patterns of MPH use among children and adults. The results from the 25-49-year-old group suggested that MPH might be being used for medical conditions other than ADHD or narcolepsy in adults, and that it might be subject to misuse and/or abuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.